EFFICACY AND SAFETY OF NANOPARTICLE ALBUMIN-BOUND PACLITAXEL VERSUS PACLITAXEL IN METASTATIC BREAST CANCER

Abstract

Purpose: To compare the efficacy and safety of nab-pacitaxel versus paclitaxel in patients with metastatic breast cancer. Patients and Methods: A total of 92 patients with metastatic breast cancer received chemotherapy for nab-palitaxel versus paclitaxel at the dose of 260mg/m2 and 175mg/m2 respectively for total 8 cycles at the Hospital of Hue University of Medicine and Pharmacy and of Hue Central Hospital from February 2013 to October 2015. Results: The mean age in two groups of patients is 54 and 53 years old. The ECOG index was 0-1 in both groups. Menopausal status accounted for 73% in 2 groups. Dominant metastatic organ sites of two groups are bone, lung, liver. Multiple sites of metastasis in nab-paclitaxel and paclitaxel groups were 18% and 20%, respectively. The response rate of patients with nab-paclitaxel was 54.5% versus 31.2% in the paclitaxel group, p = 0.024. The time to progression was 8.46 months in the nab-paclitaxel group and 7.38 months in the paclitaxel group, p = 0.019. The median survival time of the nab-paclitaxel and paclitaxel groups was 28.89 and 27.79 months, respectively, p = 0.554. Neutropenia rates in the nab-pacitaxel and paclitaxel groups were 27.3% and 39.6% respectively, p = 0.033. Other toxicities were similar in both groups. Conclusion: Nab-Paclitaxel has clinical benefits over paclitaxel in metastatic breast cancer because of higher response rate, prolonged time to progression and less neutropenia. Key words: metastatic breast cancer, nab-paclitaxel, paclitaxel